Aducanumab (Aduhelm)

Aducanumab (Aduhelm)

Aducanumab Mechanism of Action

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Aducanumab (Aduhelm)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Aducanumab (Aduhelm)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

```mermaid
flowchart TD
%% Inputs (Blue)
A["Aducanumab<br/>mAb158"]:::blue

%% Intermediates (Orange)
B["Selectively Binds<br/>Aggregated Abeta"]:::orange
C["Soluble Oligomers<br/>Primary Target"]:::orange
D["Insoluble Plaques<br/>Amyloid Fibrils"]:::orange

%% Pathology (Red)
E["Microglial<br/>Activation"]:::red
F["Fc Receptor<br/>Engagement"]:::red

%% Outcomes (Green)
G["Enhanced<br/>Phagocytosis"]:::green
H["Plaque Clearance<br/>Amyloid PET Reduction"]:::green
I["Peripheral Sink<br/>Abeta in Blood"]:::green
J["Reduced Neuritic<br/>Plaque Burden"]:::green
K["Potential Clinical<br/>Benefit"]:::green

%% Connections
A --> B
B --> C
B --> D
C --> E
D --> E
E --> F
F --> G
G --> H
A --> I
H --> J
J --> K

Aducanumab (Aduhelm)

Aducanumab Mechanism of Action

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Aducanumab (Aduhelm)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Aducanumab (Aduhelm)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

[^1]: Aducanumab binds to Abeta residues 3-7, exposed on aggregated but not monomeric forms [(Sevigny et al., 2016)](https://doi.org/10.1038/nature19323)
[^2]: EMERGE trial showed 71% amyloid PET reduction at 78 weeks [(Budd Haeberlein et al., 2022)](https://doi.org/10.1002/alz.12638)

Introduction

Aducanumab (Aduhelm) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@sevigny2016]

Overview

Aducanumab (marketed as Aduhelm) is a human monoclonal immunoglobulin gamma 1 (IgG1) antibody that was developed by Biogen in collaboration with Neurimmune for the treatment of [alzheimers](/diseases/alzheimers-disease). On June 7, 2021, aducanumab became the first anti-[amyloid-beta](/proteins/amyloid-beta) therapy to receive approval from the United States Food and Drug Administration (FDA) under the Accelerated Approval pathway, marking a watershed moment in the field of Alzheimer's therapeutics [1](https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-aduhelmtm-first-and-only) [2](https://www.ncbi.nlm.nih.gov/books/NBK573062/). The approval was based on the drug's demonstrated ability to reduce amyloid plaques in the brain—a surrogate biomarker reasonably likely to predict clinical benefit—rather than on definitive evidence of cognitive improvement ([Biogen et al., [2021](https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-aduhelmtm-first-and-only)). [@fda2021]

Aducanumab selectively targets aggregated forms of [amyloid-beta](/proteins/amyloid-beta), including soluble oligomers and insoluble fibrils that constitute the amyloid plaques characteristic of Alzheimer's pathology [2](https://www.ncbi.nlm.nih.gov/books/NBK573062/). The antibody binds to a linear epitope encompassing amino acid residues 3–7 of the [amyloid-beta](/proteins/amyloid-beta) peptide, a region exposed on aggregated but not monomeric forms of the protein. This selectivity allows aducanumab to engage pathological amyloid species while largely sparing the physiological monomer [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8491638/) ([The et al., [2016](https://doi.org/10.1038/nature19323))). [@sperling2021]

Despite its historic approval, aducanumab remained one of the most controversial drugs in the history of neurology. Biogen announced the discontinuation of aducanumab commercialization in January 2024, with the drug no longer available for purchase after November 1, 2024, as the company shifted its focus to other anti-amyloid therapies such as [lecanemab](/therapeutics/lecanemab) [4](https://www.alz.org/alzheimers-dementia/therapeutics/aducanumab). The aducanumab story offers critical lessons for drug development, regulatory science, and the application of the [amyloid-hypothesis](/mechanisms/amyloid-hypothesis) to Alzheimer's therapeutics ([Failure et al., [2021](https://doi.org/10.1002/alz.12213))). [@jack2023]

Mechanism of Action

Amyloid-Beta Targeting

Aducanumab is a fully human IgG1 monoclonal antibody derived from a library of B cells collected from cognitively healthy elderly individuals and patients with unusually slow cognitive decline. The antibody was identified through a reverse translational medicine approach: screening for naturally occurring antibodies that might confer protection against [alzheimers](/diseases/alzheimers-disease) [2](https://www.ncbi.nlm.nih.gov/books/NBK573062/) ([Alzheimer et al., [2022](https://pubmed.ncbi.nlm.nih.gov/34807243/)). [@alzheimers2021]

The antibody binds to the N-terminal region of [amyloid-beta](/proteins/amyloid-beta) (residues 3–7), recognizing a conformational epitope that is selectively exposed on aggregated forms of the peptide. This binding profile encompasses: [@fillit2021]

• Soluble oligomers: Small assemblies of [amyloid-beta](/proteins/amyloid-beta) peptides believed to be particularly neurotoxic and to impair synaptic function
• Insoluble fibrils: The major structural component of amyloid plaques deposited in the brain parenchyma
• Amyloid plaques: Dense-core and diffuse plaques composed of aggregated [amyloid-beta](/proteins/amyloid-beta) peptides [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8491638/)

Plaque Clearance Mechanism

Once bound to amyloid aggregates, aducanumab is thought to promote plaque clearance through Fc receptor-mediated phagocytosis by [microglia](/cell-types/microglia). This mechanism is shared with other anti-amyloid antibodies including [lecanemab](/therapeutics/lecanemab) and [donanemab](/therapeutics/donanemab), though each antibody targets different epitopes and amyloid conformations ([Centers et al., [2022](https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment)). [@budd2022]

Aducanumab administration produced dose- and time-dependent reductions in amyloid plaque burden as measured by amyloid PET imaging. In clinical trials, high-dose aducanumab (10 mg/kg) reduced amyloid PET signal by 59% in the ENGAGE trial, 71% in the EMERGE trial, and 61% in the Phase 1b PRIME study [1](https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-aduhelmtm-first-and-only). [@liu2021]

Clinical Development

Phase 1b PRIME Study

The Phase 1b PRIME study (NCT01677572) was a randomized, double-blind, placebo-controlled study evaluating multiple ascending doses of aducanumab in patients with prodromal or mild [alzheimers](/diseases/alzheimers-disease) with confirmed amyloid pathology by PET imaging. The study enrolled 166 patients and demonstrated: [@sims2023]

• Dose-dependent reduction of amyloid plaques
• 61% reduction in amyloid PET composite score at the highest dose (10 mg/kg) after 54 weeks
• Preliminary signals of clinical benefit on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) and Mini-Mental State Examination (MMSE) [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8491638/)

Phase 3 EMERGE and ENGAGE Trials

EMERGE (NCT02484547) and ENGAGE (NCT02477800) were two identically designed, randomized, double-blind, placebo-controlled Phase 3 studies conducted across 348 sites in 20 countries [5](https://doi.org/10.1186/s13195-021-00838-z)) [6](https://doi.org/10.14283/jpad.2022.30)](https://doi.org/10.14283/jpad.2022.30))). EMERGE enrolled 1,638 patients and ENGAGE enrolled 1,647 patients aged 50–85 years with confirmed amyloid pathology who met criteria for mild cognitive impairment (MCI) due to Alzheimer's Disease or mild Alzheimer's Disease dementia. [@van2023]

Primary Endpoint (CDR-SB at 78 weeks): [@liu2022]

• EMERGE: The primary endpoint was met. High-dose aducanumab showed a statistically significant 22% reduction in clinical decline compared with placebo (difference of −0.39 on CDR-SB; p = 0.012) [5](https://doi.org/10.1186/s13195-021-00838-z))
• ENGAGE: The primary endpoint was not met. High-dose aducanumab showed a non-significant 2% increase in clinical decline compared with placebo (difference of 0.03 on CDR-SB) [6](https://doi.org/10.14283/jpad.2022.30)](https://doi.org/10.14283/jpad.2022.30)))

• EMERGE: 71% reduction in amyloid PET composite (high dose)
• ENGAGE: 59% reduction in amyloid PET composite (high dose)
• Cumulative drug exposure was lower in ENGAGE (109.1 mg/kg) compared with EMERGE (118.3 mg/kg) due to a mid-trial protocol amendment, which may explain the discrepant clinical outcomes [6](https://doi.org/10.14283/jpad.2022.30)](https://doi.org/10.14283/jpad.2022.30)))

Safety Profile

Amyloid-Related Imaging Abnormalities (ARIA)

[aria-imaging](/entities/aria-imaging) were the most significant adverse effect observed with aducanumab treatment. ARIA encompasses two subtypes: [@cms2022]

• ARIA-E (edema/effusion): Vasogenic edema and/or sulcal effusion detected on MRI. ARIA-E occurred in 34% of participants receiving high-dose aducanumab in EMERGE and 35.5% in ENGAGE [7](https://pubmed.ncbi.nlm.nih.gov/34807243/)
• ARIA-H (hemorrhage): Microhemorrhages and superficial siderosis. ARIA-H microhemorrhage occurred in 19.1% and ARIA-H superficial siderosis in 14.7% of high-dose participants [7](https://pubmed.ncbi.nlm.nih.gov/34807243/)

Other Adverse Effects

Other commonly reported adverse effects included: [@fda2023]

• Headache (21% vs. 16% placebo)
• Falls (15% vs. 12% placebo)
• Diarrhea (9% vs. 7% placebo)
• Infusion-related reactions

Controversy and Regulatory History

FDA Advisory Committee

In November 2020, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted nearly unanimously (10 against, 1 uncertain, 0 in favor) against approval, citing the discordant results between EMERGE and ENGAGE as insufficient evidence of clinical efficacy [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8491638/). Despite this recommendation, the FDA granted accelerated approval on June 7, 2021, basing its decision on the surrogate endpoint of amyloid plaque reduction rather than on clinical benefit. [@van2023a]

The approval triggered unprecedented controversy: [@fda2023a]

• Three members of the FDA Advisory Committee resigned in protest
• The acting FDA Commissioner ordered an internal investigation into the agency's interactions with Biogen during the review process
• The Office of Inspector General launched a separate investigation
• Multiple academic commentators questioned whether amyloid plaque reduction constituted a valid surrogate for clinical benefit [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8491638/)

Medicare Coverage Decision

In April 2022, the Centers for Medicare & Medicaid Services (CMS) issued a national coverage determination limiting Medicare coverage of anti-amyloid antibodies to patients enrolled in qualifying clinical trials—a Coverage with Evidence Development (CED) framework that effectively restricted access to aducanumab [8](https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment). This decision was subsequently revised in 2023 after the traditional approval of [lecanemab](/therapeutics/lecanemab), broadening coverage for anti-amyloid antibodies with traditional FDA approval while maintaining the CED restriction for those with only accelerated approval. [@biogen2024]

Commercial Discontinuation

Following limited commercial uptake—annual revenue never exceeded $10 million against the drug's list price of approximately $26,500 per year—Biogen announced in January 2024 that it would discontinue aducanumab and withdraw its marketing authorization. The company cited a "reprioritization" of its Alzheimer's portfolio, with resources redirected toward [lecanemab](/therapeutics/lecanemab), which had received traditional FDA approval in July 2023 based on the CLARITY AD trial [4](https://www.alz.org/alzheimers-dementia/therapeutics/aducanumab). [@nih]

Legacy and Impact

Despite its commercial failure, aducanumab's development and approval had profound effects on the field: [@clarity2023]

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)/[alzheimers-disease
• [Amyloid-Targeting Therapies](/therapeutics/amyloid-targeting-therapies)/[amyloid-targeting
• [Lecanemab](/therapeutics/lecanemab)/[lecanemab
• [Clinical Trials](/clinical-trials)/[clinical-trials
• [ARIA](/entities/aria-imaging)/[aria

Background

The study of Aducanumab (Aduhelm) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@antiamyloid]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: APOE
• [Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: APOE
• [TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: TREM2
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF

Related Analyses:

• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;
• [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) &#x1f504;